Peptonic Medical

The major shareholder’s decision to exercise warrants to subscribe for shares is a clear signal of continued significant ownership commitment and a clear endorsement of Peptonic’s operations and future development.

The subscription period for TO6 expires on Friday 12 June 2026. Holders wishing to exercise their warrants must ensure that their subscription application is submitted in accordance with the instructions of their respective bank or custodian. Please note that some custodians may close their application process earlier than 12 June 2026.

For further information, please contact:
Daniel Rudeklint, Interim CEO, Peptonic Medical AB
Email: daniel.rudeklint@peptonicmedical.se
Telephone: +46 73 158 02 73

About Peptonic Medical AB
Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products for women’s intimate health. Under the VagiVital and Vernivia brands, the Company offers a range of effective and gentle over-the-counter products that help women understand, treat and prevent common gynaecological conditions. Peptonic’s growth strategy is based on geographical expansion, particularly in the US and Europe, and on continuously strengthening the product portfolio through in-house product development and strategic acquisitions.